Application of nimodipine in preparing medicine for treating acute liver injury by inducing UGT1A1

Nimodipine addresses the issue of significant side effects associated with existing drugs inducing UGT1A1 expression, achieving stable and efficient treatment of liver injury and regulation of drug metabolism, thus expanding its application in drugs for acute liver injury.

CN121015644APending Publication Date: 2025-11-28LINYI UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202511449577.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-11
Publication Date
2025-11-28

AI Technical Summary

Technical Problem

Existing drugs such as rifampin have significant side effects or poor selectivity when inducing uridine diphosphate glucuronyl transferase 1A1 (UGT1A1), and cannot effectively treat acute liver injury.

Method used

Nimodipine was used as a novel inducer to enhance the expression and enzyme activity of UGT1A1 in the preparation of drugs for the treatment of acute liver injury, particularly in the regulation of drug metabolism and the treatment of hyperbilirubinemia.

Benefits of technology

Nimodipine induces stable UGT1A1 expression with low cytotoxicity, significantly increases UGT1A1 mRNA and protein expression levels, enhances bilirubin and drug metabolism, and provides a new strategy for personalized drug therapy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of nimodipine in preparation of a medicine for treating acute liver injury by inducing UGT1A1, and belongs to the technical field of regulation and control of metabolic enzymes of medicines. According to the application of nimodipine in preparation of the medicine for treating acute liver injury by inducing UGT1A1, nimodipine can induce expression of UGT1A1, and the mRNA and protein expression level of enzyme can be remarkably up-regulated. The invention can be used for regulating drug metabolism, hyperbilirubinemia and other diseases caused by insufficient expression of UGT1A1. The application range of nimodipine is expanded, and a new strategy is provided for individualized drug therapy.
Need to check novelty before this filing date? Find Prior Art